Author: admin

Modelworks Direct Leads the Way in Post-Pandemic Business Innovation

Leading model manufacturer adjusts strategies to meet the new global business environment.

June 21, 2024 – As businesses worldwide recover from the COVID-19 pandemic, Modelworks Direct, under the leadership of Senior Partner Herman Bongco, is at the forefront of innovative strategies that redefine business models. The company has effectively embraced teleworking and diversified its approach to business, demonstrating resilience and adaptability in these challenging times.

Adapting to a New Business Landscape

In response to the disruptions caused by the pandemic, many businesses, including Modelworks Direct, have shifted to teleworking. This transition has ensured continuity and opened doors to creative business strategies and innovative marketing approaches. “The pandemic challenged many of our clients to rethink how we operate,” commented Bongco. “We’ve seen an increase in the acceptance of teleworking and a willingness to explore new ideas to keep businesses dynamic and responsive.

“According to the company, Modelworks Direct has diversified its marketing strategies to include a blend of traditional and digital approaches. Utilizing social media platforms, Google Ads, and other online marketing tools, the company has expanded its reach and engaged with a broader audience. “Innovation in marketing is essential,” Bongco stated. “We’ve had success in using social media to connect with clients and showcase our custom models, which are a unique offering in the market.”

Custom Models as Unique Business Gifts

One of the standout strategies Modelworks Direct has adopted is offering custom models as business gifts. This approach enhances brand visibility and provides clients with a memorable and tangible token of appreciation. The company’s range of custom models includes large-scale airplane models, diecast cars, and memorabilia, all of which can be tailored to meet specific client needs. These models serve as a powerful marketing tool, strengthening client relationships and promoting the brand in a distinctive way.

Expertise and Craftsmanship

Modelworks Direct is renowned for its high-quality custom models fabricated by a team of experienced architects, fabricators, and builders. With over 40 years of experience, the company prides itself on producing models that are not only accurate but also meticulously crafted. “Our models are more than just replicas; they are pieces of art,” Bongco emphasizes. “We use the finest materials and ensure each model is hand-painted for historical accuracy and authenticity.”

As the only owner-operated model builder with actual hands-on experience in the industry, Modelworks Direct holds memberships in prestigious organizations such as the National Business Aviation Association (NBAA), Aircraft Operators and Pilots Association (AOPA), and Experimental Aircraft Association (EAA). These affiliations underscore the company’s commitment to excellence and its standing as a leader in the field.

Modelworks Direct is dedicated to providing its clients with the highest level of satisfaction. The company offers a 100 percent money-back guarantee on its models, ensuring customers receive products that meet their specifications. “We stand behind our work,” remarked Bongco. “Our clients can trust that they will receive models that are crafted with precision and care.”

For more information, please visit Modelworks Direct at http://www.modelworksdirect.com or call 1-844-8MODELS.

About Modelworks Direct:

Based in San Dimas, California, Modelworks Direct is a premier producer of custom-scale models. The company offers an extensive range of products, including airplanes, helicopters, ships, and more. Each model is created based on client photos and specifications, ensuring a unique and personalized product.

Media Contact
Company Name: Modelworks Direct
Contact Person: Media Relations
Email: Send Email
City: San Dimas
State: California
Country: United States
Website: http://www.modelworksdirect.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Modelworks Direct Leads the Way in Post-Pandemic Business Innovation

Endometrial Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Endometrial Cancer Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Endometrial Cancer pipeline landscape. It covers the Endometrial Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Endometrial Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Endometrial Cancer Research. Learn more about our innovative pipeline today! @ Endometrial Cancer Pipeline Outlook

 

Key Takeaways from the Endometrial Cancer Pipeline Report

  • June 2024:- Merch Sharp & Dohme LLC– A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001). The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for progression-free survival (PFS) per Response Evaluation Criteria In Solid Tumors version 1.
  • June 2024:- Faeth Therapeutics– A Randomized, Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced or Recurrent Endometrial Cancer. This is a Phase 2, multicenter, open-label, randomized study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel and the efficacy and safety of serabelisib with paclitaxel versus paclitaxel alone in participants with advanced or recurrent endometrial cancer.
  • June 2024:- Karyopharm Therapeutics Inc.– A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma.The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.
  • DelveInsight’s Endometrial Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Endometrial Cancer treatment.
  • The leading Endometrial Cancer Companies such as Merck & Co, ImmunoGen, Mersana Therapeutics, Volastra Therapeutics, Inc, BeiGene/Jazz Pharmaceuticals, Iconic Therapeutics, AstraZeneca/Daiichi Sankyo, Apollomics, Tempest Therapeutics, Totus Medicines, TORL Biotherapeutics, Tango Therapeutics, Theratechnologies, Synthon, Klus Pharma, Seagen, Karyopharm Therapeutics, Inspirna, Chimerix, and others.
  • Promising Endometria Cancer Therapies such as Sacituzumab Govitecan, Ataluren + Pembrolizumab, Olaparib, Lenvatinib, Paclitaxel, BMS- 986205, Sapanisertib, Serabelisib, and others.

 

Stay informed about the cutting-edge advancements in Endometrial Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Endometrial Cancer Clinical Trials Assessment

 

Endometrial Cancer Emerging Drugs Profile

LENVIMA: Merck & Co

Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. LENVIMA is being developed in combination with KEYTRUDA. LENVIMA is being developed in collaboration with Eisai. Currently, the drug is in Phase III stage of its development for the treatment of endometrial cancer.

Mirvetuximab soravtansine: ImmunoGen

Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. Currently, the drug is in Phase II stage of its development for the treatment of endometrial cancer.

XMT 1660: Mersana Therapeutics

XMT-1660 is a B7-H4-directed Dolasynthen ADC with a precise, target-optimized drug-to-antibody ratio (DAR 6) and a proprietary payload with controlled bystander effect. B7-H4 is overexpressed in a range of cancers, including breast, endometrial and ovarian tumors. B7-H4 (VTCN1) exerts immunosuppressive effects by suppression of T cell proliferation and is expressed on tumor-associated macrophages (TAMs) as well as epithelial tumor cells. Currently, the drug is in Phase I stage of its development for the treatment of endometrial cancer.

VLS-1488: Volastra Therapeutics, Inc.

VLS-1488 is a potent oral KIF18A inhibitor with the potential to be the first-ever chromosomal instability-targeted cancer therapy. VLS-1488 and sovilnesib (formally AMG650) make up Volastra’s innovative clinical portfolio of differentiated KIF18A inhibitors specifically designed for the treatment of solid tumors characterized by high levels of chromosomal instability (CIN). Currently, the drug is in Phase I/II stage of its development for the treatment of endometrial cancer.

 

Learn more about Endometrial Cancer Drugs opportunities in our groundbreaking Endometrial Cancer Research and development projects @ Endometrial Cancer Unmet Needs

 

Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular

 

Endometrial Cancer Products have been categorized under various Molecule types such as

  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies

 

Discover the latest advancements in Endometrial Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Endometrial Cancer Market Drivers and Barriers, and Future Perspectives

 

Scope of the Endometrial Cancer Pipeline Report

  • Coverage- Global
  • Endometrial Cancer Companies- Merck & Co, ImmunoGen, Mersana Therapeutics, Volastra Therapeutics, Inc, BeiGene/Jazz Pharmaceuticals, Iconic Therapeutics, AstraZeneca/Daiichi Sankyo, Apollomics, Tempest Therapeutics, Totus Medicines, TORL Biotherapeutics, Tango Therapeutics, Theratechnologies, Synthon, Klus Pharma, Seagen, Karyopharm Therapeutics, Inspirna, Chimerix, and others.
  • Endometria Cancer Therapies- Sacituzumab Govitecan, Ataluren + Pembrolizumab, Olaparib, Lenvatinib, Paclitaxel, BMS- 986205, Sapanisertib, Serabelisib, and others.
  • Endometrial Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Endometrial Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Endometrial Cancer Pipeline on our website @ Endometrial Cancer Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Endometrial Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Endometrial Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. LENVIMA: Merck & Co
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Mirvetuximab soravtansine: ImmunoGen
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. VLS-1488: Volastra Therapeutics, Inc.
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Endometrial Cancer Key Companies
  21. Endometrial Cancer Key Products
  22. Endometrial Cancer – Unmet Needs
  23. Endometrial Cancer – Market Drivers and Barriers
  24. Endometrial Cancer – Future Perspectives and Conclusion
  25. Endometrial Cancer Analyst Views
  26. Endometrial Cancer Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Endometrial Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Primary Biliary Cholangitis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Primary Biliary Cholangitis Pipeline Insight 2024” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Primary Biliary Cholangitis pipeline landscape. It covers the Primary Biliary Cholangitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Primary Biliary Cholangitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Primary Biliary Cholangitis Research. Learn more about our innovative pipeline today! @ Primary Biliary Cholangitis Pipeline Outlook

 

Key Takeaways from the Primary Biliary Cholangitis Pipeline Report

  • June 2024:- Zydus Therapeutics Inc.- A Multicenter, Open-Label, Extension Clinical Trial to Evaluate Safety and Efficacy of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis (PBC). A Multicenter, Open-Label, Extension Clinical trial to evaluate Safety and Efficacy of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis (PBC).
  • June 2024:- CymaBay Therapeutics Inc.- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis. To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
  • June 2024:- COUR Pharmaceuticals Development Company Inc.- A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 With Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA. This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.
  • June 2024:- Calliditas Therapeutics Suisse SA– The primary objective of this study is to evaluate the effect of setanaxib on alkaline phosphatase (ALP) at Week 24 in participants with PBC and with elevated liver stiffness and intolerance or inadequate response to ursodeoxycholic acid (UDCA).
  • June 2024:- Ipsen– A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease of the liver that leads to injury and destruction of bile ducts.
  • June 2024:- Mirum Pharmaceuticals, Inc.- A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis. The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.
  • June 2024:- GlaxoSmithKline– A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC). This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.
  • DelveInsight’s Primary Biliary Cholangitis pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Primary Biliary Cholangitis treatment.
  • The leading Primary Biliary Cholangitis Companies such as Genfit, Zydus Discovery, Ohara Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Novartis, CymaBay Therapeutics, and others.
  • Promising Primary Biliary Cholangitis Therapies such as Saroglitazar Magnesium 1 mg, Seladelpar 10 mg, Obeticholic Acid Tablets, and others.

 

Stay informed about the cutting-edge advancements in Primary Biliary Cholangitis Treatments. Download for updates and be a part of the revolution in cancer care @ Primary Biliary Cholangitis Clinical Trials Assessment

 

Primary Biliary Cholangitis Emerging Drugs Profile

  • Elafibranor: Genfit

Elafibranor is a dual agonist of the PPARα and PPARδ. Meaning the drug candidate acts simultaneously on the two nuclear receptors, which both play an important role in numerous processes involved in the development of NASH and its co-morbidities. It has shown highly significant results in its Phase 2 Study in patients with primary biliary cholangitis (PBC), while maintaining a favorable tolerability profile and lack of demonstrated safety concerns, paving the way for advancement into phase 3 clinical trial in 2020. It has recently been granted Breakthrough Therapy Designation by the FDA for the treatment of Primary Biliary Cholangitis (PBC) in adults with inadequate response to ursodeoxycholic acid (UDCA), as well as Orphan Drug Designation by the FDA and the EMA (European Medicines Agency).

  • ASC42: Gannex Pharma

ASC42 is a novel non-steroidal, selective, potent FXR agonist. It has shown positive results in its Phase I Study in patients with primary biliary cholangitis with no pruritus observed and LDL-C remained within normal range at the human therapeutic dose of 15 mg. The drug is in Phase II stage of its clinical studies for Primary Biliary Cholangitis.

  • OP-724: Ohara Pharmaceutical

OP-724 is a synthetic small molecule which is an inhibitor of cyclic AMP response element-binding protein (CREB)-binding protein (CBP)/β-catenin. Ohara Pharmaceutical obtained development rights for OP-724 from PRISM BioLab in 2018 . The drug is in Phase I stage of its clinical studies for Primary Biliary Cholangitis.

 

Learn more about Primary Biliary Cholangitis Drugs opportunities in our groundbreaking Primary Biliary Cholangitis Research and development projects @ Primary Biliary Cholangitis Unmet Needs

 

Primary Biliary Cholangitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Primary Biliary Cholangitis Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Discover the latest advancements in Primary Biliary Cholangitis Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Primary Biliary Cholangitis Market Drivers and Barriers, and Future Perspectives

 

Scope of the Primary Biliary Cholangitis Pipeline Report

  • Coverage- Global
  • Primary Biliary Cholangitis Companies- Genfit, Zydus Discovery, Ohara Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Novartis, CymaBay Therapeutics, and others.
  • Primary Biliary Cholangitis Therapies- Saroglitazar Magnesium 1 mg, Seladelpar 10 mg, Obeticholic Acid Tablets, and others.
  • Primary Biliary Cholangitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Primary Biliary Cholangitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Primary Biliary Cholangitis Pipeline on our website @ Primary Biliary Cholangitis Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Primary Biliary Cholangitis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Primary Biliary Cholangitis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Elafibranor: Genfit
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. ASC42: Gannex Pharma
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. OP-724: Ohara Pharmaceutical
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Primary Biliary Cholangitis Key Companies
  18. Primary Biliary Cholangitis Key Products
  19. Primary Biliary Cholangitis- Unmet Needs
  20. Primary Biliary Cholangitis- Market Drivers and Barriers
  21. Primary Biliary Cholangitis- Future Perspectives and Conclusion
  22. Primary Biliary Cholangitis Analyst Views
  23. Primary Biliary Cholangitis Key Companies
  24. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Primary Biliary Cholangitis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Multiple System Atrophy Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Multiple System Atrophy Pipeline Insight 2024” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Multiple System Atrophy pipeline landscape. It covers the Multiple System Atrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple System Atrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Multiple System Atrophy Research. Learn more about our innovative pipeline today! @ Multiple System Atrophy Pipeline Outlook

 

Key Takeaways from the Multiple System Atrophy Pipeline Report

  • June 2024:- H. Lundbeck A/S– This study will consist of a double-blind period (DBP) and will include an optional open-label treatment extension (OLE) period. Participants in the DBP will be randomized to Lu AF82422 or placebo (2:1). All participants entering the OLE will receive Lu AF82422 during the OLE.
  • June 2024:- Theravance Biopharma– A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants With Multiple System Atrophy. This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE).
  • June 2024:- Vertex Pharmaceuticals Incorporated- A Phase 1/2, Randomized, Double-blind, Placebo-controlled Single- and Multiple-dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type 1. The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.
  • June 2024:- BioMarin Pharmaceutical- This is Phase 1/2, open-label, multi-center study consisting of 2 parts to evaluate the safety and tolerability of BMN 351 at escalating doses in participants with Duchenne Muscular Dystrophy (DMD) with genetic mutations amenable to exon 51 skipping. The purpose of this study is to test the safety and tolerability of BMN 351 in participants with Duchenne Muscular Dystrophy (DMD) with a genetic mutation amenable to exon 51 skipping.
  • June 2024:- Dyne Therapeutics– The primary purpose of this study is to evaluate the safety, tolerability, and dystrophin protein levels in muscle tissue following multiple intravenous (IV) doses of DYNE-251 in participants with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.
  • June 2024:- ARTHEx Biotech S.L.- A Phase 1/2a Double-Blind, Placebo-controlled, Single- and Multiple Ascending Dose Study to Assess the Safety, Tolerability, PK, PD and Efficacy of IV Administration of ATX-01 In Male and Female Participants Aged 18 to 64 With Classic DM1. The goal of this clinical trial is to test ATX-01 in participants with myotonic dystrophy type 1 (DM1). The main question it aims to answer is if ATX-01 is safe and well tolerated. The trial will compare the safety and tolerability of ATX-01 and a matching placebo.
  • DelveInsight’s Multiple System Atrophy pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Multiple System Atrophy treatment.
  • The leading Multiple System Atrophy Companies such as Theravance Biopharma, Alterity Therapeutics, AskBio, Kainos Medicines, CORESTEM Inc., ProMIS Neuroscience, H. Lundbeck A/S, and others.
  • Promising Multiple System Atrophy Therapies such as Lu AF82422, hOMSC300, TAK-341, KM-819, ONO-2808, Ampreloxetine, Nusinersen, OAV101, and others.

 

Stay informed about the cutting-edge advancements in Multiple System Atrophy Treatments. Download for updates and be a part of the revolution in cancer care @ Multiple System Atrophy Clinical Trials Assessment

 

Multiple System Atrophy Emerging Drugs Profile

  • Ampreloxetine: Theravance Biopharma

Ampreloxetine, an investigational, novel, selective, long-acting, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). The unique benefits of ampreloxetine treatment reported in MSA patients from Study 0170 included an increase in norepinephrine levels, a favorable impact on blood pressure, clinically meaningful and durable symptom improvements, and no signal for supine hypertension. The company has been granted an orphan drug designation in the US and, if results support it, plans to file an NDA for full approval based on the Phase III CYPRESS study. The drug is currently investigated in Phase III clinical trial for MSA patients.

  • ATH434: Alterity Therapeutics

ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase I studies demonstrating the agent is well tolerated and achieved brain levels comparable to efficacious levels in animal models of MSA. ATH434 is currently being studied in two clinical trials: Study ATH434-201 is a randomized, double-blind, placebo-controlled Phase II clinical trial in patients with early-stage MSA and Study ATH434-202 is an open-label Phase II Biomarker trial in patients with more advanced MSA. ATH434 has been granted Orphan drug designation for the treatment of MSA by the US FDA and the European Commission.

  • AB-1005: AskBio

AB-1005 is an investigational gene therapy based on adeno-associated viral vector serotype 2 (AAV2) containing the human glial cell line-derived neurotrophic factor (GDNF) transgene, which allows for stable and continuous expression of GDNF in localized regions of the brain after direct neurosurgical injection with magnetic resonance imaging (MRI)-monitored convection enhanced delivery. GDNF is a homodimer that is a distantly related member of the transforming growth factor-β superfamily. In midbrain neuronal cell cultures, recombinant human GDNF promoted the survival and morphological differentiation of dopaminergic neurons and increased their high-affinity dopamine uptake.

 

Learn more about Multiple System Atrophy Drugs opportunities in our groundbreaking Multiple System Atrophy Research and development projects @ Multiple System Atrophy Unmet Needs

 

Multiple System Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Multiple System Atrophy Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Discover the latest advancements in Multiple System Atrophy Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Multiple System Atrophy Market Drivers and Barriers, and Future Perspectives 

 

Multiple System Atrophy Companies and Therapies

  • Theravance Biopharma: Ampreloxetine
  • Biogen: Nusinersen
  • Novartis Pharmaceuticals: OAV101
  • GeneCradle Inc.: GC101
  • Hoffmann- La Roche: RO7204239

 

Scope of the Multiple System Atrophy Pipeline Report

  • Coverage- Global
  • Multiple System Atrophy Companies- Theravance Biopharma, Alterity Therapeutics, AskBio, Kainos Medicines, CORESTEM Inc., ProMIS Neuroscience, H. Lundbeck A/S, and others.
  • Multiple System Atrophy Therapies- Lu AF82422, hOMSC300, TAK-341, KM-819, ONO-2808, Ampreloxetine, Nusinersen, OAV101, and others.
  • Multiple System Atrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Multiple System Atrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Multiple System Atrophy Pipeline on our website @ Multiple System Atrophy Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Multiple System Atrophy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Multiple System Atrophy – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Ampreloxetine: Theravance Biopharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. ATH434: Alterity Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. AB-1005: AskBio
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Multiple System Atrophy Key Companies
  21. Multiple System Atrophy Key Products
  22. Multiple System Atrophy- Unmet Needs
  23. Multiple System Atrophy- Market Drivers and Barriers
  24. Multiple System Atrophy- Future Perspectives and Conclusion
  25. Multiple System Atrophy Analyst Views
  26. Multiple System Atrophy Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple System Atrophy Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Chronic Myelomonocytic Leukaemia Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Chronic Myelomonocytic Leukaemia Pipeline Insight 2024” report provides comprehensive insights about 22+ companies and 25+ pipeline drugs in Chronic Myelomonocytic Leukaemia pipeline landscape. It covers the Chronic Myelomonocytic Leukaemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myelomonocytic Leukaemia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Chronic Myelomonocytic Leukaemia Research. Learn more about our innovative pipeline today! @ Chronic Myelomonocytic Leukaemia Pipeline Outlook

 

Key Takeaways from the Chronic Myelomonocytic Leukaemia Pipeline Report

  • June 2024:- Douglas Tremblay- This is a phase 1/2 trial of pacritinib in combination with azacitidine in patients with Chronic Myelomonocytic Leukemia (CMML). Patients will be newly diagnosed or previously treated but could not have received a prior JAK inhibitor. Patients who have previously been treated with a hypomethylating agent (HMA) must have received ≤ 1 cycle.
  • June 2024:- Novartis Pharmaceuticals– An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.
  • June 2024:- M.D. Anderson Cancer Center- This phase I/II trial studies the side effects and best dose of venetoclax in combination with cedazuridine and decitabine (ASTX727) in treating patients with high risk myelodysplastic syndrome or chronic myelomonocytic leukemia who have not received prior treatment (treatment-naive). Chemotherapy drugs, such as venetoclax, cedazuridine, and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
  • June 2024:- Otsuka Australia Pharmaceutical Pty Ltd- A Phase 3b, Randomized, Open-Label, Double Crossover Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Adult Patients With IPSS R Intermediate Myelodysplastic Syndrome, Low Blast Acute Myeloid Leukemia, IPSS Intermediate-2 or High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia.
  • June 2024:- Astex Pharmaceuticals, Inc.:– Study ASTX030-01 is designed to move efficiently from Phase 1 to Phase 3. Phase 1 consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose Expansion Stage (Stage B) of ASTX030. Phase 2 is a randomized open-label crossover study to compare oral ASTX030 to subcutaneous (SC) azacitidine. Phase 3 is a randomized open-label crossover study comparing the final oral ASTX030 dose to SC azacitidine. The duration of the study is expected to be approximately 48 months.
  • June 2024:- Cogent Biosciences, Inc.- A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis. This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
  • DelveInsight’s Chronic Myelomonocytic Leukaemia pipeline report depicts a robust space with 22+ active players working to develop 25+ pipeline therapies for Chronic Myelomonocytic Leukaemia treatment.
  • The leading Chronic Myelomonocytic Leukaemia Companies such as Novartis, Humanigen, Incyte Corporation, Genetech, Celgene, AbbVie, Amgen, Nerviano Medical Sciences, Guangzhou Lupeng Pharmaceutical, and others.
  • Promising Chronic Myelomonocytic Leukaemia Therapies such as Bezuclastinib, CPX-351, Cyclophosphamide, Cyclosporine, Azacitidine, Enasidenib, APG 2575 ramp up arm, and others.

 

Stay informed about the cutting-edge advancements in Chronic Myelomonocytic Leukaemia Treatments. Download for updates and be a part of the revolution in cancer care @ Chronic Myelomonocytic Leukaemia Clinical Trials Assessment

 

Chronic Myelomonocytic Leukaemia Emerging Drugs Profile

  • Sabatolimab: Novartis

Sabatolimab (MBG 453) is an anti T-cell immunoglobulin and mucin domain 3 (anti-TIM3) monoclonal antibody that is being developed by Novartis Oncology. Currently, the drug is in Phase III stage of development for the treatment of Chronic Myelomonocytic Leukaemia.

  • Ruxolitinib: Incyte Corporation

Ruxolitinib (Jakafi) is a first-in-class inhibitor of the JAK1 and JAK2 protein kinases and works by competitively inhibiting the ATP-binding catalytic site on JAK1 and JAK2. The result of this inhibition is disruption of cytokine and growth factor signaling pathways, leading to a decrease in proinflammatory cytokines and chemokines. In the clinical study, Ruxoltinib demonstrated meaningful clinical activity in CMML patients with splenomegaly and/or high disease symptom burden. The drug is already approved by the US Food and Drug Administration for the treatment of people with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF. Jakafi is also indicated for the treatment of people with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. The drug is currently in Phase II stage of development for the treatment of Chronic Myelomonocytic Leukaemia.

  • NMS-03592088: Nerviano Medical Sciences

NMS-03592088 (NMS-088) is a potent inhibitor of FLT3, KIT, and CSF1R kinases. NMS-088 is the most active compound among the FLT3 comparators, a finding especially evident in the presence of the FLT3 “gatekeeper mutation,” which is associated with clinical resistance to treatment with other FLT3 inhibitors. There is a rationale for the use of the molecule in Chronic Myelomonocytic Leukemia (CMML) on the basis of the demonstrated inhibition of CSF1R, a highly expressed and activated target in this tumor type. The drug is currently in the Phase I/II stage of development for the treatment of CMML.

  • LP-108: Guangzhou Lupeng Pharmaceutical

LP-108 is a proto-oncogene protein (c-bcl-2) inhibitor. The drug is currently in Phase I stage of development for the treatment of CMML.

 

Learn more about Chronic Myelomonocytic Leukaemia Drug opportunities in our groundbreaking Chronic Myelomonocytic Leukaemia Research and development projects @ Chronic Myelomonocytic Leukaemia Unmet Needs

 

Chronic Myelomonocytic Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Chronic Myelomonocytic Leukaemia Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Discover the latest advancements in Chronic Myelomonocytic Leukaemia Treatment by visiting our website. Stay informed about how we’re transforming the future @ Chronic Myelomonocytic Leukaemia Market Drivers and Barriers, and Future Perspectives 

 

Chronic Myelomonocytic Leukaemia Companies and Therapies

  • Cogent Bioscience Inc.:- Bezuclastinib
  • Ascentage Pharma Group Inc.:- APG 2575 ramp up arm
  • BioLite Inc.:- BLEX 404 Oral Liquid
  • Astex Pharmaceuticals Inc.:- Azacitidine

 

Scope of the Chronic Myelomonocytic Leukaemia Pipeline Report

  • Coverage- Global
  • Chronic Myelomonocytic Leukaemia Companies- Novartis, Humanigen, Incyte Corporation, Genetech, Celgene, AbbVie, Amgen, Nerviano Medical Sciences, Guangzhou Lupeng Pharmaceutical, and others.
  • Chronic Myelomonocytic Leukaemia Therapies- Bezuclastinib, CPX-351, Cyclophosphamide, Cyclosporine, Azacitidine, Enasidenib, APG 2575 ramp up arm, and others.
  • Chronic Myelomonocytic Leukaemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Chronic Myelomonocytic Leukaemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Chronic Myelomonocytic Leukaemia Pipeline on our website @ Chronic Myelomonocytic Leukaemia Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Chronic Myelomonocytic Leukaemia: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Chronic Myelomonocytic Leukaemia– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Sabatolimab : Novartis
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Ruxolitinib: Incyte Corporation
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. NMS-03592088: Nerviano Medical Sciences
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Chronic Myelomonocytic Leukaemia Key Companies
  21. Chronic Myelomonocytic Leukaemia Key Products
  22. Chronic Myelomonocytic Leukaemia- Unmet Needs
  23. Chronic Myelomonocytic Leukaemia- Market Drivers and Barriers
  24. Chronic Myelomonocytic Leukaemia- Future Perspectives and Conclusion
  25. Chronic Myelomonocytic Leukaemia Analyst Views
  26. Chronic Myelomonocytic Leukaemia Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Myelomonocytic Leukaemia Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Advanced Non-Squamous & Squamous NSCLC Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Advanced Non-Squamous & Squamous NSCLC Pipeline Insight, 2024,” report provides comprehensive insights about 9+ companies and 11+ pipeline drugs in Advanced Non-Squamous & Squamous NSCLC pipeline landscape. It covers the Advanced Non-Squamous & Squamous NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Non-Squamous & Squamous NSCLC therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Advanced Non-Squamous & Squamous NSCLC Research. Learn more about our innovative pipeline today! @ Advanced Non-Squamous & Squamous NSCLC Pipeline Outlook

 

Key Takeaways from the Advanced Non-Squamous & Squamous NSCLC Pipeline Report

  • June 2024:- Summit Therapeutics– A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi).
  • June 2024:- AstraZeneca– The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
  • June 2024:- AbbVie– A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.
  • June 2024:- Arcus Biosciences Inc.– A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. This is a phase 3 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) compared to pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic NSCLC.
  • June 2024:- Genelux Corporation– A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician’s Choice of Immune Checkpoint Inhibitor Compared With Docetaxel in Patients With NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance.
  • June 2024:- Boehringer Ingelheim- Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations.
  • June 2024:- Mabscale LLC-BEV-III/2022 is a double-blind randomized multicenter clinical trial comparing efficacy of bevacizumab (manufactured by Mabscale, LLC) and paclitaxel plus carboplatin to Avastin® and paclitaxel plus carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC. The purpose of the study is to demonstrate equivalence of efficacy and safety of bevacizumab (manufactured by Mabscale, LLC) to Avastin®.
  • DelveInsight’s Advanced Non-Squamous & Squamous NSCLC pipeline report depicts a robust space with 9+ active players working to develop 11+ pipeline therapies for Advanced Non-Squamous & Squamous NSCLC treatment.
  • The leading Advanced Non-Squamous & Squamous NSCLC Companies such as Jiangsu Alphamab Biopharmaceuticals, Jiangsu HengRui Medicine, Novartis Pharmaceuticals, Genentech, and others.
  • Promising Advanced Non-Squamous & Squamous NSCLC Therapies such as Pembrolizumab, Bevacizumab, Pemetrexed, RBN-2397, Tiragolumab, Pyrotinib, Docetaxel, SAR408701 (Tusamitamab ravtansine), and others.

 

Stay informed about the cutting-edge advancements in Advanced Non-Squamous & Squamous NSCLC Treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Non-Squamous & Squamous NSCLC Clinical Trials Assessment

 

Advanced Non-Squamous & Squamous NSCLC Emerging Drugs Profile

 

  • Erfonrilimab: Jiangsu Alphamab Biopharmaceuticals

KN-046 (Erfonrilimab) is a bispecific antibody targeting both programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The drug is currently being evaluated under the Phase III clinical trial for the treatment of Advanced Squamous Non-small Cell Lung Cancer.

  • Pyrotinib: Jiangsu HengRui Medicine

Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients suffering from advanced non-squamous NSCLC.

 

Learn more about Advanced Non-Squamous & Squamous NSCLC Drugs opportunities in our groundbreaking Advanced Non-Squamous & Squamous NSCLC Research and development projects @ Advanced Non-Squamous & Squamous NSCLC Unmet Needs

 

Advanced Non-Squamous & Squamous NSCLC pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Subcutaneous
  • Intravitreal
  • Intramuscular

 

Advanced Non-Squamous & Squamous NSCLC Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

 

Discover the latest advancements in Advanced Non-Squamous & Squamous NSCLC Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Advanced Non-Squamous & Squamous NSCLC Market Drivers and Barriers, and Future Perspectives

 

Advanced Non-Squamous & Squamous NSCLC Companies and Drugs

  • Ribon Therapeutics Inc.: RBN-2397
  • Summit Therapeutics:- AK112 Injection
  • Jiangsu HengRui Medicine Co., Ltd.:- Pyrotinib/Docetaxel
  • Sanofi:- SAR408701 (Tusamitamab ravtansine)
  • Shanghai Shengdi Pharmaceutical Co., Ltd:- Adebrelimab+SHR-8068+Pemetrexed+Carboplatin

 

Scope of the Advanced Non-Squamous & Squamous NSCLC Pipeline Report

  • Coverage- Global
  • Advanced Non-Squamous & Squamous NSCLC Companies- Jiangsu Alphamab Biopharmaceuticals, Jiangsu HengRui Medicine, Novartis Pharmaceuticals, Genentech, and others.
  • Advanced Non-Squamous & Squamous NSCLC Therapies- Pembrolizumab, Bevacizumab, Pemetrexed, RBN-2397, Tiragolumab, Pyrotinib, Docetaxel, SAR408701 (Tusamitamab ravtansine), and others.
  • Advanced Non-Squamous & Squamous NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Advanced Non-Squamous & Squamous NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Non-Squamous & Squamous NSCLC Pipeline on our website @ Advanced Non-Squamous & Squamous NSCLC Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Non-Squamous & Squamous NSCLC: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Non-Squamous & Squamous NSCLC – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Pyrotinib: Jiangsu HengRui Medicine
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Drug name: Company name
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug name: Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Advanced Non-Squamous & Squamous NSCLC Key Companies
  21. Advanced Non-Squamous & Squamous NSCLC Key Products
  22. Advanced Non-Squamous & Squamous NSCLC- Unmet Needs
  23. Advanced Non-Squamous & Squamous NSCLC- Market Drivers and Barriers
  24. Advanced Non-Squamous & Squamous NSCLC- Future Perspectives and Conclusion
  25. Advanced Non-Squamous & Squamous NSCLC Analyst Views
  26. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Non-Squamous & Squamous NSCLC Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

New Fantasy Novel by Cameo Renae Explores a Dark World of Vampires, Kingdoms, and a Young Woman’s Fight for Survival

New Fantasy Novel by Cameo Renae Explores a Dark World of Vampires, Kingdoms, and a Young Woman’s Fight for Survival

21st June, 2024 – Bestselling author Cameo Renae is set to captivate readers with her latest novel, “Of the Blood,” the first instalment in the four-part “Heir of Blood and Fire” series. This gripping fantasy saga introduces us to Calla Caldwell, a young woman whose life is upended by a chance encounter with a mysterious vampire prince, setting in motion a tale of dark secrets, rival kingdoms, and a fight for survival.

Raised in a continent ravaged by generations of war, Calla leads a quiet life—until she meets Trystan Vladu, a charming and enigmatic stranger. Drawn in by his seductive allure, Calla discovers that Trystan is no ordinary man but the prince of Morbeth, a kingdom with a dark history. In a moment of passion, his bite irrevocably changes her, making her a part of a conflict far larger than she ever imagined.

Calla’s new reality is harsh and unforgiving. She’s captured, tortured, and starved in a dungeon, victim to the malevolent forces that have ruled Morbeth for generations. But hope arrives through a séance with a witch of light, where Calla contacts a long-lost relative—a Princess of Incendia—who leaves her with a gift. This mysterious power could be the key to defeating the forces of darkness if Calla can learn to control it.

As secrets and betrayals unravel, Calla must navigate a landscape filled with danger and deception. Allies are few and far between, and the stakes are higher than ever. With the malevolent Prince of Morbeth determined to reclaim her, Calla is thrust into a battle for her life and the survival of those she holds dear.

“Of the Blood” is a thrilling exploration of dark fantasy, blending elements of romance, suspense, and supernatural power into a story that will keep readers on the edge of their seats. Cameo Renae’s deft storytelling and vivid world-building create an immersive experience that invites readers to lose themselves in the dangerous and enchanting world of Calla Caldwell.

“Of the Blood” is available now wherever books are sold. Get ready to embark on a journey filled with intrigue, danger, and the intoxicating allure of the unknown.

About the Author

Cameo was born in San Francisco, raised in Maui, Hawaii, and now resides with her husband in Las Vegas. She is a dreamer and caffeine addict who loves to laugh and loves to read to escape reality.

One of her greatest satisfactions is creating fantasy worlds filled with adventure and romance. It is the love and incredible support of her family and fans that keeps her going. One day she hopes to uncover a magic wardrobe and ride away on a unicorn. Until then . . . she’ll keep writing!

Website: www.cameorenae.com

Join Club Cameo on FB: https://www.facebook.com/groups/CameoRenaeFanClub/

Book Name: Of the Blood (Heir of Blood and Fire Book 1)

Author Name: Cameo Renae

ISBN Number: 978-1735046709

Kindle Version: Click Here

Paperback Version: Click Here

Hardcover Version: Click Here

Media Contact
Company Name: Book Publishing Plus
Email: Send Email
Phone: +1-201-977-0753
Address:100 Overlook Center
City: Princeton
State: New Jersey
Country: United States
Website: https://bookpublishingplus.com/

Transform Your Life in Just 30 Days: Trevor Atkinson’s New Book Offers a Blueprint for Personal Growth and Healing

Transform Your Life in Just 30 Days: Trevor Atkinson's New Book Offers a Blueprint for Personal Growth and Healing

Author and personal development expert Trevor Atkinson is proud to announce the release of his transformative new book, “Change Your Life in 30 Days: A Guide to Personal Transformation.” This empowering guide is designed to help readers embrace a journey of self-discovery and transformation, providing a clear, actionable roadmap for achieving lasting change in just one month.

In “Change Your Life in 30 Days,” Atkinson combines his expertise in psychology, self-development, and mindfulness to create a comprehensive guide that empowers readers to heal from past wounds, reframe limiting beliefs, and cultivate resilience and growth. Through daily exercises and reflections, readers learn how to create a more intentional and fulfilling life.

Key features of the book include:

  • Daily Practices: Readers are guided through practical exercises and reflections designed to spark insight, promote healing, and encourage growth each day.
  • Inspiring Stories: Atkinson shares relatable personal stories and anecdotes that illustrate the power of transformation and guide readers on their journey.
  • Holistic Approach: The book addresses the emotional, cognitive, and behavioral aspects of change, providing a well-rounded approach to personal growth.
  • Focus on Compassion: Atkinson emphasizes the importance of self-compassion and mindfulness, encouraging readers to navigate their transformation journey with kindness and understanding.
  • Tools for Lasting Change: Readers will gain access to various tools, including journaling prompts, cognitive restructuring exercises, and mindfulness practices.

“Change Your Life in 30 Days” is a valuable resource for anyone seeking to take charge of their life and embark on a path of personal transformation. Atkinson’s clear, accessible writing style and practical approach make the book a must-read for those looking to create meaningful, positive change.

About the Author

Trevor Atkinson, an Honors degree Psychologist, Hypnotherapist and Master Practitioner of Neuro-Linguistic Programming, is a seasoned Mind coach with over a decade of experience. He empowers individuals to overcome obstacles and propel their lives forward, specializing in guiding transformative journeys. Having studied across Europe, North America, and Asia, Trevor’s expertise transcends borders. His counseling expertise extends to fostering healthy connections, aiding those grappling with personal challenges, and nurturing emotional well-being. Trevor’s approach encompasses understanding and overcoming life’s stressors, ensuring mental resilience. In his practice, he skillfully navigates clients through relational intricacies, empowering them to embark on meaningful self-discovery and fostering positive behavioral shifts.

Book Name: Change Your Life in 30 Days: A Guide to Personal Transformation

Author Name: Trevor Atkinson

ISBN Number: 1917238916

Ebook Version: Click Here

Paperback Version: Click Here

Media Contact
Company Name: Book Publishing Plus
Email: Send Email
Phone: +1-201-977-0753
Address:100 Overlook Center
City: Princeton
State: New Jersey
Country: United States
Website: https://bookpublishingplus.com/

Unveiling “S.H.E”: A Riveting Tale of Resistance and Survival in a Dystopian Future

Unveiling "S.H.E": A Riveting Tale of Resistance and Survival in a Dystopian Future

Stephen R Godfrey’s Debut Novel Paints a Harrowing Picture of Marginalized Women Fighting for Freedom in 2050

In a world reimagined and reshaped by societal upheavals, Stephen R. Godfrey’s debut novel, “S.H.E.”, takes readers on a gripping journey into a dystopian future where women are marginalized, and society is ruled by a harsh communist regime. Set in the summer of 2050, “S.H.E.” is a tale of defiance, courage, and resilience that captivates from the first page to the last.

Since the collapse of capitalist markets in the late 2030s, most of the world has embraced communist governments. In the United Kingdom, the regime is particularly oppressive, relegating women to domestic roles and enforcing hard labor on men in fields and mines. Against this backdrop, “S.H.E” tells the story of a group of brave women led by Jessica and Maggie who dare to challenge the status quo. Forming pockets of resistance in northern London, these women risk everything in their fight for justice and equality.

Stephen R Godfrey, a writer in his seventies, brings a wealth of life experience to his work. Having traveled extensively and witnessed various systems and ways of life, Godfrey infuses his novel with authenticity and depth. As the senior member of a large family with three children and nine grandchildren, Godfrey’s insights into familial bonds and societal roles add a profound layer to the narrative. His love for the English language and its nuances is evident in the rich, compelling prose that drives “S.H.E”.

What sets “S.H.E” apart is its relentless pace and the strength of its characters. Readers will find themselves deeply invested in the fates of Jessica, Maggie, and their fellow rebels as they navigate the dangers of their oppressive society. The novel is a poignant exploration of how dictatorial regimes can corrupt and exploit, presenting a chilling vision of a future that serves as a cautionary tale for the present.

“S.H.E” is not just a story of resistance; it is a stark reminder of the dangers of societal complacency and the power of solidarity. The book delves into themes of subjugation and the fight for a better future, making it a must-read for anyone interested in dystopian fiction, women’s rights, and political intrigue. The depiction of ‘breeding centres’ and the enforced separation of families is particularly harrowing, painting a vivid picture of the regime’s brutality.

About the Author:

After spending most of his life, working in Europe and the Middle East Stephen is now enjoying his retirement in the Wolds of Yorkshire in northern England and spends his time writing and playing the guitar. Back in the late sixties and early seventies, Stephen played in several rock bands and still enjoys listening to classic rock bands, including Led Zeppelin and The Smashing Pumpkins. Whilst this is his first published novel, he has a couple of projects on the go, one of which is the follow-up to S.H.E. (S.H.E. (2)). Stephen has a large family and is the proud ‘gramps’ to no less than nine grandchildren, which keeps him occupied when he’s not in his study writing.

Book Name: S.H.E

Author Name: Stephen R Godfrey

ISBN Number: 196378927X

Ebook Version: Click Here

Hardcover: Click Here

Paperback Version: Click Here

Media Contact
Company Name: Global Publishing Agency
Email: Send Email
Phone: 5626141989
Address:5000 E Spring St
City: Long Beach
State: California 90815
Country: United States
Website: https://globalpublishingagency.com/

Genopets Launches New Apple Vision Pro App: Transforming Fitness and Digital Companionship

As the world becomes increasingly digital, finding compelling incentives to lead healthier lives is more crucial than ever. Enter Genopets, the mobile app that gamifies healthy habits, transforming self-care into a fun and rewarding adventure with a personalized digital companion. In Genopets, daily steps convert into Energy, helping players level up and evolve their pets while also leveling up themselves.

Introducing the Apple Vision Pro App

Genopets is committed to leveraging the latest technology to benefit players. The game economy is built on the blockchain, ensuring true ownership of in-game items. Currently, Genopets is developing a GenAI Adventure Mode to further motivate players to explore the real world and unlock a personalized AI lore of the Genoverse. To deepen the bonds players share with their Genopets, they have also developed a new companion app for the Apple Vision Pro.

https://youtu.be/cKFCRgbuja4 

The Apple Vision Pro app brings Genopets into the real world, allowing players to interact with them in a new dimension. Imagine watching movies with a Genopet or working beside one while it chills in its Habitat, like a digital terrarium. Viewing a Genopet in this way brings childhood dreams to life.

Features of the Apple Vision Pro App

–  360-Degree View: See digital pets from every angle.

–  Room Placement: Place a Genopet anywhere in any room.

–  Scalable Size: Scale them up to life-size or enjoy them in a floating Habitat.

Discover New Genopets

Explore unique Genopets without signing in. View randomly generated Genopets—each one different in stage, color, and Augments. Once a player scrolls past a Genopet, they won’t see it again, making each encounter unique and exciting. This feature allows players to explore the diverse possibilities within the Genoverse and get inspired to customize their own Genopet in the app using Cosmetic Crystals and Augments.

Future Enhancements

The current app developed for the Apple Vision Pro is just the beginning. The goal is to continue encouraging healthy habits with even more social and interactive features, including:

–  Pomodoro Timer: Audible reminders for stretch breaks.

–  Interactive Play: Feed, pet, and play with a Genopet using user touch and movements.

–  Social Engagement: Play with friends over SharePlay with Genopet races.

The Genopets team is incredibly excited about the potential of this new technology to expand the Genoverse and make the player experience more immersive and rewarding. Stay tuned for more updates as they continue to innovate and bring these digital companions to life in new ways.

About Genopets

Genopets is a mobile app that gamifies fitness, turning a player’s steps into Energy they can use to level up their digital pet and themself. Built on the blockchain, Genopets ensures true ownership of in-game items and offers an engaging way to stay active and healthy.

For more information, visit their website or check them out on X.

Media Contact
Company Name: Genopets
Contact Person: Maggie Dorfman
Email: Send Email
Country: United States
Website: https://www.genopets.me/